Article,
A review on nanoparticles targeting cervical and endometrial cancer
World Journal of Biology Pharmacy and Health Sciences, 12 (3): 146–159 (December 2022)
DOI: 10.30574/wjbphs.2022.12.3.0219
Abstract
The two most frequent gynecological cancers in women globally are cervical and endometrial cancers. Despite the fact that a variety of medications have been created for treatment, they frequently result in a number of negative side effects, toxicity, and multidrug resistance (MDR). Despite the fact that surgery and chemo radiotherapy can cure 80–95 percent of women with early-stage cancer, recurring and metastatic disease remains a leading cause of cancer death. To address this, scientists have taken advantage of the benefits afforded by nano systems, such as nanocarriers in the fields of tumor targeting, increased drug accumulation in tumors, and so on. The major characteristics of this system include biodegradability, biocompatibility, non-toxicity, prolonged circulation, and a large payload range of a therapeutic drug. Anticancer treatment side effects can be decreased by encapsulating the drug and delivering it directly to the cancer site. Drug release at cancer locations using stimuli responsive nanocarriers is effective for achieving target-specific delivery. When compared to the conventional system, these methods exhibit improved ability to target malignant cells without harming healthy cells and offer the promise for advanced cancer therapy. Recent breakthroughs in intrinsic and extrinsic-stimulus sensitive nanomaterial systems for drug administration in cancer therapy, as well as other polymeric nano particles employed in cancer therapy, are discussed in this study.
